Growing Incidence of Urinary Tract Infections Fuels Europe Overactive Bladder Treatment Market Growth
Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells, and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities can further damage the integrity of the urothelial barrier. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Moreover, as per the National Institute for Health and Care Excellence organization, UTIs are among the most common hospital-acquired infections in the UK, accounting for ~23% of all infections. According to the BMC Family Practice, UTI consultations accounted for ~2% of ED visits in the Netherlands in 2019. Similarly, in France, ~4–6 million people suffer from UTI each year. Thus, the increasing incidence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the Europe overactive bladder treatment market growth.
Europe Overactive Bladder Treatment Market Overview
The Europe overactive bladder treatment market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global overactive bladder treatment market and is estimated to register a substantial CAGR over the forecast period. The growing demand for overactive bladder treatment due to the presence of the geriatric population is driving the market growth in Europe. Further, the prevalence of neurological diseases and diabetes hampering urinary tract functions is likely to create opportunities for the growth of overactive bladder treatment in the coming years. According to the UK Parliament’s data, approximately one-fifth of the total UK population was aged 65 and above in 2019. Besides, the number of people in this age group increased by 23% from 2009 to 2019, while the total UK population increased by only 7% during the same period. Diabetes UK states that ~3.9 million people were diagnosed with diabetes in 2019, and it reached 4.7 million in 2021. The rising prevalence of diabetes and the growing elderly population in the UK lead to surging cases of overactive bladder condition, thereby stroking the demand for its treatment.
Europe Overactive Bladder Treatment Market Segmentation
The Europe overactive bladder treatment market is segmented into pharmacotherapy, disease type, and country.
The Europe overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.
AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the overactive bladder treatment market in Europe.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,111.05 Million |
| Market Size by 2028 | US$ 1,318.55 Million |
| CAGR (2022 - 2028) | 2.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Pharmacotherapy
|
|
Regions and Countries Covered
|
|
| Europe | UK, Germany, France, Russia, Italy, Rest of Europe |
| Market leaders and key company profiles |
|
The Europe Overactive Bladder Treatment Market is valued at US$ 1,111.05 Million in 2022, it is projected to reach US$ 1,318.55 Million by 2028.
As per our report Europe Overactive Bladder Treatment Market, the market size is valued at US$ 1,111.05 Million in 2022, projecting it to reach US$ 1,318.55 Million by 2028. This translates to a CAGR of approximately 2.9% during the forecast period.
The Europe Overactive Bladder Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Overactive Bladder Treatment Market report:
The Europe Overactive Bladder Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Overactive Bladder Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Overactive Bladder Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)